β-Blocker usage and colorectal cancer mortality: A nested case-control study in the UK clinical practice research datalink cohort

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3100-3106

  Hicks, Blánaid ^a   Murray, L J ^a   Powe, D G ^b,c   Hughes, C M ^a   Cardwell, C R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Atenolol; Colorectal cancer survival; Medication; Pharmacoepidemiology; Propranolol; blockers

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; LABETALOL; METOPROLOL; NEBIVOLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; UNITED KINGDOM; VERY ELDERLY;

ATENOLOL; COLORECTAL CANCER SURVIVAL; MEDICATION; PHARMACOEPIDEMIOLOGY; PROPRANOLOL; Β-BLOCKERS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROPRANOLOL; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84888814629     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt381     Document Type: Article

References (25)

1. Yang EV, Sood AK, Chen M et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66(21): 10357-10364.
2. Weddle DL. beta-Adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001; 22(3): 473-479.
3. Masur K, Niggemann B, Zanker KS et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by {beta}-blockers. Cancer Res 2001; 61(7): 2866-2869.
4. Pérez Piñero C, Bruzzone A, Sarappa MG et al. Involvement of α2-and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 2012; 166(2): 721-736.
5. Yang EV, Kim S, Donovan EL et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stressrelated enhancement of tumor progression. Brain Behav Immun 2009; 23(2): 267-275.
6. Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 2009; 124(2): 257-263.
7. Kozanoglu I, Yandim MK, Cincin ZB et al. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. J Cancer Res Clin Oncol 2013; 139(2): 327-335.
8. Lin X, Luo K, Lv Z et al. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology 2012; 59(114): 584-588.
9. Zhang D, Yong Ma Q, Hu H-T et al. β 2-Adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-κB and AP-1. Cancer Biol Ther 2010; 10(1): 19-29.
10. Lin Q, Wang F, Yang R et al. Effect of chronic restraint stress on human colorectal carcinoma growth in mice. PLoS One 2013; 8(4): e61435.
11. Barron TI, Connolly RM, Sharp L et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011; 29(19): 2635-2644.
12. Powe DG, Voss MJ, Zänker KS et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1(7): 628-638.
13. Wang HM, Liao ZX, Komaki R et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 2013; 24(5): 1312-1319.
14. Grytli HH, Fagerland MW, Fosså SD et al. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2013 January 14 [epub ahead of print], doi: 10.1016/j.eururo.2013.01.007.
15. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012; 127(2): 375-378.
16. Zmora O. β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from:http://clinicaltrials.gov/show/NCT00888797 (29 April 2013, date last accessed).
17. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302(6779): 766-768.
18. Khan NF, Perera R, Harper S et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010; 11: 1.
19. Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiacvalve regurgitation. N engl J Med 2007; 356(1): 29-38.
20. Lévesque LE, Hanley JA, Kezouh A et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.
21. Etminan M. Pharmacoepidemiology II: the nested case-control study-a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004; 24(9): 1105-1109.
22. Essebag V, Platt RW, Abrahamowicz M et al. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5(1): 5.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
24. Shah SM, Carey IM, Owen CG et al. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011; 72(1): 157-161.
25. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival versus cancer-specific survival. Int J Epidemiol 2010; 39(2): 598-610.